Brief: Avalo Advances Btla Agonist Fusion Protein (Avtx-008) To Ind-Enabling Stage

Avalo Therapeutics

06/09/2022 12:42

Sept 6 (Reuters) - Avalo Therapeutics Inc  AVTX.O :
    * AVALO ADVANCES BTLA AGONIST FUSION PROTEIN (AVTX-008) TO
IND-ENABLING STAGE

Source text for Eikon:  ID:nGNX5d0bk5 
Further company coverage:  AVTX.O 

 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))